AbbVie Receives U.S. FDA Approval Of VIEKIRA PAK(TM) (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) For The Treatment Of Chronic Genotype 1 Hepatitis C >ABBV

Press/Media: Press / Media

PeriodDec 20 2014

Media coverage

1

Media coverage

  • TitleAbbVie Receives U.S. FDA Approval Of VIEKIRA PAK(TM) (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) For The Treatment Of Chronic Genotype 1 Hepatitis C >ABBV
    Media name/outletiMarketReports
    CountryUnited States
    Date12/20/14
    PersonsFred Poordad